Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18077932 | 1.00 | VSIR (0.43) | VSIRCD274S1PR1DPP4DPP7 | |
| SCHEMBL18077943 | 0.91 | VSIR (0.48) | VSIRCD274S1PR1DPP4DPP7 | |
| SCHEMBL19867021 | 0.91 | VSIR (0.48) | VSIRCD274S1PR1DPP4DPP7 | |
| SCHEMBL18077936 | 0.88 | CD274 (0.58) | VSIRCD274S1PR1DPP4DPP7 | |
| SCHEMBL19867093 | 0.88 | CD274 (0.58) | VSIRCD274S1PR1DPP4DPP7 | |
| SCHEMBL19981256 | 0.86 | VSIR (0.44) | VSIRCD274S1PR1LMNATSHR | |
| SCHEMBL19981254 | 0.86 | KCNT1 (0.47) | VSIRCD274LMNATSHRFOLH1 | |
| SCHEMBL19981275 | 0.79 | DPP4 (0.47) | VSIRCD274DPP4DPP7LMNA | |
| SCHEMBL19981233 | 0.78 | LMNA (0.44) | S1PR1LMNATSHRCTSAHDAC6 | |
| SCHEMBL19866982 | 0.77 | VSIR (0.45) | VSIRCD274LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044329-A1 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044329-A1 | 3-SUBSTITUTED-1,2,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | PDCD1, CD274, PDCD1LG2 | VSIR 2158/4885CD274 2/4885S1PR1 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.